Tagged: Omicron Variant

From the beginning, pharmaceutical companies engaged in the development of COVID-19 vaccine were aware that to defeat the pandemic they had to address proactively virus variants. Moderna in a Nov. 2021 press release (https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Strategy-to-Address-Omicron-B.1.1.529-SARS-CoV-2-Variant/default.aspx) stated that a 100-µg booster dose of the Moderna approved COVID-19 vaccine is studied for protection against the Omicron variant. In addition, the […]

Several SARS-CoV-2 variants have been identified since the beginning of the COVID-19 pandemic: Alpha (B.1.1.7 and Q lineages) Beta (B.1.351 and descendent lineages) Gamma (P.1 and descendent lineages) Epsilon (B.1.427 and B.1.429) Eta (B.1.525) Iota (B.1.526) Kappa (B.1.617.1) 1.617.3 Mu (B.1.621, B.1.621.1) Zeta (P.2) On November 30, 2021, the U.S. government SARS-CoV-2 Interagency Group (SIG) […]